A5055948821- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Liver Disease Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Cystic Fibrosis Research Advances
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Diet and metabolism studies
- Statistical Methods in Clinical Trials
- Pharmacology and Obesity Treatment
- COVID-19 and Mental Health
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Artificial Intelligence in Healthcare
- SARS-CoV-2 and COVID-19 Research
- Heart Failure Treatment and Management
- COVID-19 epidemiological studies
- Diet, Metabolism, and Disease
- Child Nutrition and Feeding Issues
- Lipoproteins and Cardiovascular Health
- Renal Diseases and Glomerulopathies
- Diabetes Management and Education
Nightingale Hospital
2016-2025
Indian Ocean Medical Trading (Somalia)
2022
Manipal Hospital
2016
Apollo Gleneagles Hospitals
2016
Creative Research Enterprises (United States)
2016
Indraprastha Apollo Hospitals
2014-2016
Sir Ganga Ram Hospital
2016
St. Luke's-Roosevelt Hospital Center
2016
Osmania Medical College
2014
CARE Hospitals
2014
<title>Abstract</title> Background: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) worldwide. Identifying clinical and laboratory associations with CKD in T2D can assist physicians targeting modifiable risk factors. In light limited data from India, CITE (CKD Indian Evaluation) study was conducted. Methods: The multicenter, cross-sectional included 3,325 patients 28 centres across India over three months. defined as a persistent decline function (eGFR < 60...
<title>Abstract</title> Background and Aim: Hepatic fibrosis is a critical complication of metabolic disorders, particularly in patients with Type 2 Diabetes (T2D). This study aimed to evaluate the performance Fibrosis-4 index (Fib 4) score detecting significant (transient elastography [TE] ≥ 8 kPa) identify key predictors advanced using logistic regression analysis T2D. Methods: retrospective included propensity-matched T2D non-T2D patients. Sensitivity, specificity, Cohen's Kappa were used...
Abstract Aims and Methods Effect of angiotensin converting enzyme inhibitors (ACEi) receptor blockers (ARB) on outcomes in patients with coronavirus disease 2019 (COVID-19) is uncertain. Available evidence limited to a few retrospective observational studies small number patients. We did meta-analysis assess the effect ACEi/ARB COVID-19 severity disease, risk for hospitalisation, death compared those not ACEi/ARB. searched Cochrane library, PubMed, Embase, ClinicalTrial.gov medRxiv published...
Sodium glucose cotransporter 2 inhibitors (SGLT-2i), by way of their unique mode action, present an attractive strategy for the treatment type diabetes and non-alcoholic fatty liver disease (NAFLD), which often coexist may lead to severe complications. However, evidence with SGLT-2i is limited small heterogeneous studies. Therefore, this meta-analysis was conducted deduce effects in NAFLD (T2D).A web-based search identified nine randomized controlled trials from Cochrane Library, Embase,...
Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP1RA), is available in both parenteral and oral preparations. Studies of injectable preparations have convincingly demonstrated its beneficial effect on major adverse cardiac events (MACE). This predictive analysis was undertaken to forecast early termination the SOUL trial (oral semaglutide) as well primary events. multicenter, double-blind, placebo-controlled randomized controlled (RCT) evaluating reduction MACE associated with...
Abstract Objective There are no controlled studies on the role of systemic corticosteroids (CS) in patients with coronavirus disease 2019 (COVID-19). In absence high-quality evidence, understandably recommendations from various organizations cautious. Several randomized trials underway but shall take time to conclude. We therefore undertook a meta-analysis ascertain CS management critically ill COVID-19. Data Sources Electronic databases, including Pubmed, Cochrane library and Embase, were...
Therapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation SGLT2i GLP-1RA in DURATION 8 trial an improvement HbA1c was noted but beneficial effect not equal to sum its parts. In view this we proceeded test hypothesis that sequential addition therapy metformin SGLT-2i may be more beneficial.A retrospective real world...
<h3>OBJECTIVE</h3> To investigate gastric emptying and intestinal transit of pelleted pancreatin in relation to food boluses. <i>Methods—</i>Dual isotope scintigraphy combined with breath hydrogen sampling was used track the concurrent of<sup>111</sup>indium labelled microspheres a<sup>99m</sup>technetium tin colloid test meal. Twelve pancreatic insufficient cystic fibrosis patients aged 5 38 years performed study. <h3>RESULTS</h3> 50% times showed patient variation. The mean discrepancy...
Although the positive effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on hospitalization for heart failure in type 2 diabetes (T2D) seem definite, some doubt exists about their atherosclerotic cardiovascular disease (ASCVD). This study aims to shed light this debatable issue. An electronic database search (Cochrane Library, PubMed and Embase) was performed using two groups terms ["sodium glucose cotransporter2 inhibitor", "dapagliflozin", "canagliflozin", "empagliflozin",...